New drug combo trial aims to tame aggressive nasal cancer
NCT ID NCT07385079
Summary
This study is testing whether adding the drug anlotinib to the current standard treatment (immunotherapy plus chemotherapy and radiation) works better for people with high-risk, locally advanced nasopharyngeal cancer. It will enroll 412 adults to compare the two treatment approaches. The main goal is to see if the new combination helps patients live longer without their cancer coming back or spreading.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.